ArticleThe Lancet. Oncology2023

Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma - Authors' reply.

Thomas Powles et al.PubMed ↗Publisher ↗

No numbers read from the abstract.